LOG IN
SIGN UP
MARKET
PRPO
PRPO
Precipio Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
1.110
+0.050
+4.72%
After Hours: 1.160 +0.05 +4.50% 17:20 07/01 EDT
OPEN
1.050
PREV CLOSE
1.060
HIGH
1.120
LOW
1.050
VOLUME
67.40K
TURNOVER
0
52 WEEK HIGH
4.170
52 WEEK LOW
0.9100
MARKET CAP
25.21M
P/E (TTM)
-2.1171
1D
5D
1M
3M
1Y
5Y
Keith Meadors Joins Precipio to Lead its Products Division
Seasoned, experienced industry executive with a track record of managing 9-figure revenue sales organizationsNEW HAVEN, Conn., June 13, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO), today announced that Keith...
GlobeNewswire · 06/13 15:00
BRIEF-Precipio Receives CE-IVD Certification To Market Multiple Hemescreen® Panels In Europe
reuters.com · 05/24 18:10
Precipio Reports Received CE-IVD Approval For Sale Of Its HemeScreen Reagents In European Union
Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ:PRPO), today announced that it has received CE-IVD approval for sale of its HemeScreen® reagents in the European Union. The approval was provided
Benzinga · 05/24 14:30
Precipio Receives CE-IVD Certification to Market Multiple HemeScreen® Panels in Europe
This Regulatory Approval Opens the Company’s Reach to the European MarketNEW HAVEN, Conn., May 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO), today announced that it has received CE-IVD approval for sale o...
GlobeNewswire · 05/24 14:30
Precipio Shares Rise on Regulatory Approval for Sale of Screening Technology in European Union
MT Newswires · 05/24 11:15
When Will Precipio, Inc. (NASDAQ:PRPO) Breakeven?
We feel now is a pretty good time to analyse Precipio, Inc.'s ( NASDAQ:PRPO ) business as it appears the company may be...
Simply Wall St. · 05/11 12:15
BRIEF-Precipio Signs First Iv-Cell Customer Agreement
reuters.com · 05/10 15:24
Precipio Signs First IV-Cell Customer Agreement
Laboratory operating both HemeScreen® & IV-Cell® demonstrates significant cross-sell potentialNEW HAVEN, Conn., May 10, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that American Oncology Netw...
GlobeNewswire · 05/10 14:30
No Data
Learn about the latest financial forecast of PRPO. Analyze the recent business situations of Precipio Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 1 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PRPO stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
Current 1.110
EPS
Actual
Estimate
-0.16-0.12-0.08-0.04
Institutional Holdings
Institutions: 27
Institutional Holdings: 2.42M
% Owned: 10.64%
Shares Outstanding: 22.71M
TypeInstitutionsShares
Increased
4
10.28K
New
1
13.28K
Decreased
7
140.85K
Sold Out
5
139.49K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+1.68%
Healthcare Equipment & Supplies
+1.92%
Key Executives
Non-Executive Chairman/Independent Director
Richard Sandberg
Chief Executive Officer/Founder/Director
Ilan Danieli
Chief Financial Officer
Matthew Gage
Chief Operating Officer
Ahmed Zaki Sabet
Vice President - Research & Development
Ayma A. Mohamed
Independent Director
Ronald Andrews
Independent Director
David Cohen
Independent Director
Jeffrey Cossman
Independent Director
Douglas Fisher
Independent Director
Kathleen Laporte
No Data
No Data
About PRPO
Precipio, Inc. is a healthcare solutions company that is focused on cancer diagnostics. The Company is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a cell culture media that addresses the problem of selective and serial culturing. IV-Cell is a media that enables culturing of all four hematopoietic cell lineages, which include myeloid cells, B-cells, T-cells and plasma cells. The diagnostic process of hematopoietic diseases involves chromosomal analysis by conducting cell-culture-based tests in a cytogenetics laboratory to imitate in-vivo conditions. HemeScreen technology was developed by the Company targeting Myeloproliferative Neoplasms (MPN), which has evolved into a suite of robust genetic diagnostic panels. ICP technology was developed at Harvard and is licensed exclusively by Dana-Farber. Its laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha.
Webull offers kinds of Precipio Inc stock information, including NASDAQ:PRPO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRPO stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading PRPO stock methods without spending real money on the virtual paper trading platform.